Edwards Lifesciences Corp (EW) Holdings Raised by Capital Management Associates NY

Capital Management Associates NY grew its holdings in Edwards Lifesciences Corp (NYSE:EW) by 33.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,800 shares of the medical research company’s stock after acquiring an additional 945 shares during the quarter. Capital Management Associates NY’s holdings in Edwards Lifesciences were worth $662,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in EW. Private Capital Group LLC bought a new position in shares of Edwards Lifesciences during the second quarter worth about $112,000. Centaurus Financial Inc. bought a new position in shares of Edwards Lifesciences during the second quarter worth about $114,000. SRS Capital Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 317.5% during the third quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after buying an additional 508 shares in the last quarter. LFA Lugano Financial Advisors SA bought a new position in shares of Edwards Lifesciences during the third quarter worth about $121,000. Finally, Signet Financial Management LLC bought a new position in shares of Edwards Lifesciences during the second quarter worth about $136,000. Institutional investors own 82.71% of the company’s stock.

In other news, CFO Scott B. Ullem sold 25,036 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $140.04, for a total value of $3,506,041.44. Following the completion of the sale, the chief financial officer now directly owns 41,019 shares of the company’s stock, valued at $5,744,300.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, October 29th. The shares were sold at an average price of $140.74, for a total value of $4,630,346.00. The disclosure for this sale can be found here. Insiders have sold 150,311 shares of company stock valued at $21,718,936 over the last three months. Insiders own 1.84% of the company’s stock.

EW has been the subject of a number of research reports. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Saturday, July 14th. Northland Securities reiterated a “hold” rating and set a $120.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and set a $168.00 price objective on shares of Edwards Lifesciences in a report on Friday, July 27th. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Finally, Wells Fargo & Co increased their price objective on Edwards Lifesciences from $152.00 to $170.00 and gave the stock an “outperform” rating in a report on Friday, July 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. Edwards Lifesciences has an average rating of “Buy” and a consensus price target of $156.79.

Shares of NYSE EW opened at $157.15 on Friday. Edwards Lifesciences Corp has a 52 week low of $103.20 and a 52 week high of $175.00. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18. The company has a market cap of $31.93 billion, a P/E ratio of 34.17, a P/E/G ratio of 2.01 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The firm had revenue of $906.60 million during the quarter, compared to analysts’ expectations of $927.56 million. During the same period in the prior year, the firm posted $0.84 earnings per share. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Corp will post 4.7 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/11/09/edwards-lifesciences-corp-ew-holdings-raised-by-capital-management-associates-ny.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: Understanding each part of a balance sheet

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply